Caring for Individuals with Intellectual and Developmental Disabilities in the COVID-19 Crisis

Authors: Jessica Solomon Sanders, MD; Seth Keller, MD; Bhooma R. Aravamuthan, MD, DPhil

Bhooma Aravamuthan, Division of Pediatric Neurology, Department of Neurology, Washington University School of Medicine, St. Louis, MO
Jessica Solomon Sanders, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA
Seth Keller, Neurology Associates of South Jersey, Lumberton NJ

Search Terms: All Neurology, COVID-19, Developmental Disorders, Cerebral Palsy, Autism

Submission Type: Commentary

Title Character Count: 93
Number of Tables: 3
Number of Figures: 0

Neurology® Clinical Practice Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Word count of Abstract: 76
Word Count of Paper:

**Corresponding Author:** Bhooma R. Aravamuthan
Division of Pediatric Neurology, Department of Neurology, Washington University School of Medicine
660 South Euclid Avenue, Campus Box 8111
St. Louis, MO, 63110-1093, USA
Tel: +1 314 780 7875, Fax: +1 314 454 4225, e-mail: aravamuthanb@wustl.edu

Jessica Solomon Sanders Jessica.sanders@childrens.harvard.edu
Seth Keller Seth Keller sethkeller@aol.com

**Financial Disclosures:**
Bhooma Aravamuthan – Receives research funding from the National Institute of Neurological Disorders and Stroke
Jessica Solomon Sanders – Reports no disclosures.
Seth Keller – Reports no disclosures.

**Study Funded** by NINDS (5K12NS098482-02)
Abstract:

Individuals with intellectual and developmental disabilities (IDD) are amongst our most medically vulnerable neurologic patient population. As such, they are at particular risk of psychosocial and medical harm during the COVID-19 pandemic. Here we highlight strategies to decrease potential infectious exposures and ensure continued optimal neurologic care for individuals with IDD during the COVID-19 pandemic. Finally, in a climate of potential medical resource restriction, we offer some suggestions for advocacy on behalf of individuals with IDD.

Individuals with intellectual and developmental disabilities (IDD) comprise a large proportion of neurology patients. Their myriad diagnoses include cerebral palsy, Down syndrome, and Autism Spectrum Disorder, with many of these disorders co-morbid with each other. Their abilities range from complete functional independence to complete functional dependence with variable requirements at baseline for life-sustaining supports such as home ventilators, gastrostomy tubes, or personal care assistants (PCAs). Even mild medical illnesses can exacerbate many difficulties patients with IDD face including managing muscle tone, difficulty feeding, or behavioral challenges. Though the coronavirus disease 2019 (COVID-19) pandemic has made us all feel vulnerable, patients with IDD are particularly at risk of functional deterioration. At the time of this writing, the number of worldwide cases has climbed above 3 million. The US harbors 1 million of those infected and is reporting case-fatality rates of 2-9%.

Adults with IDD maybe living in group homes; the support staff and associated organizations are likely under enormous pressure to ensure that COVID-19 does not create internal chaos. Upholding a routine schedule, ensuring safety, happiness, and health maintenance are all paramount.

Routine neurology visits are critical for early detection of emerging or worsening symptoms of cognitive impairment, epilepsy, depression, or increased tone. In the setting of a significant social, economic, and medical stressor like the COVID-19 pandemic, these routine visits become even more critical. Prior to the COVID-19 pandemic, adoption of tele-neurology services had been growing, though slowly. Barriers to use of tele-neurology have included lack of affordable HIPAA compliant platforms, lack of insurance reimbursement for services rendered, and lack of familiarity on the part of medical providers and patients. By necessity, tele-neurology has become the primary option for non-emergent health care consultation in the setting of this pandemic.
Here we highlight strategies to capitalize upon tele-neurology to decrease potential infectious exposures and ensure continued optimal neurologic care for individuals with IDD during the COVID-19 pandemic.

**Strategies for preventative tele-neurology**

At this point in the pandemic, there is a tendency to cancel “non-urgent” or “routine” follow-up appointments with plans to reschedule in 2-3 months. Frequently, the 2-3 month delay is expanding to a 5-6 month delay as guidelines restricting non-essential business continue to extend. For individuals with IDD, postponing neurologic follow-up for 2-3 months, or longer, could be catastrophic. As individuals with IDD may be a population that is highly vulnerable to adverse outcomes if infected with the coronavirus, it is important to maintain contact with this fragile group. Now is the time to invest in HIPAA-compliant video-based tele-health services or utilize telephone visits to continue to check in on these vulnerable patients. Strategies for implementation of tele-neurology have been outlined recently by the AAN and Neurology Live in webinar format and also by the AAN Telemedicine Working Group prior to the pandemic.

As individuals with IDD have diverse needs and diverse etiologies, common care guidelines across this population do not yet formally exist. However, during the COVID-19 pandemic, there are key care features regarding ongoing health maintenance and crisis anticipation.

1. Re-affirm the value of physical distancing while mitigating the associated challenges.

Physical distancing is the best-known method for preventing coronavirus exposure. However, deviance from one’s typical daily routine, loss of inter-personal and therapeutic interactions, and limited circadian light exposure can exacerbate psychiatric co-morbidities and sleep difficulties for patients with IDD. Encourage time outdoors with spaces isolated from others (e.g. a backyard or a balcony) and open windows during the day. Also encourage adherence to a daily routine including bathing, dressing, exercising, and engaging in productive activities in the main living space of the home during the day. Advocate that patients engage in similar wind-down activities at nighttime. Maintenance of a routine can help establish some continuity of lifestyle in this time of uncertainty.

2. Ensure adequate medication refills.

Minimizing trips to the pharmacy is critical in the interest of physical distancing. Discuss mail-order pharmacies with your patients. If this is not a feasible option, consider prescribing three-month supplies of medications instead of one-month supplies. Some health insurance companies are allowing for longer duration refills in the setting of this pandemic. Let the insurance companies know that longer duration refills will be one of the primary ways you can keep your patients safe.

3. Ensure that providers, patients, and caregivers all share an understanding of the patient’s healthy baseline.
These tele-neurology visits are a good time to revisit your understanding and your patient’s understanding of their baseline level of functioning and status of medical co-morbidities. During this pandemic, it is best to ensure that all neurologic concerns are optimized to allow the best buffer in case of infection. Some suggested specifics to establish/reaffirm are offered in Table 1.


Individuals with IDD have a much higher rate of abuse compared to the general population. During the global pandemic, patients with IDD are particularly at risk of the consequences of worsening mental health symptoms in themselves and of their caregivers.

Table 2 provides recommendations for screening and crisis management planning.

5. Set pre-determined requirements for in-person visits.

It is best at this time to postpone in-person visits for at least 2-3 months. Beyond scheduled baclofen pump refills, many visits for patients with IDD can be accomplished virtually. Patients who rely on botulinum toxin or phenol injections in many cases may be able to temporarily be managed with increases in other tone-related medications, specifically with night-time dosing. Consider whether injectable therapies are providing improvements in pain and/or functionality and how these resultant issues may be otherwise temporarily addressed. If injectable therapies are absolutely required, which they may be for many of your patients, try to bundle this visit in with any other requirement for the family to visit the hospital.

Previously scheduled office visits to discuss ongoing seizure management, behavioral assessments, cognitive evaluations, and other neurologic concerns should not be postponed because of the COVID-19 crisis. These visits, if at all possible, should be converted to phone or video-based tele-neurology visits. Maintaining oversight on chronic neurologic conditions is mandatory to ensure that these various personal and health challenges do not lead to unforeseen disruptions.

6. Evaluate caregiving needs.

Consider empiric screening of caregivers for depression and anxiety. Caregivers cannot adequately care for your patients if they themselves are unwell. Ensure that they have access to a reputable online social network of other caregivers to help with coping with the unusual levels of stress and uncertainty they are currently facing. Examples include CPDailyLiving, CPNOW, National Down Syndrome Society, Spina Bifida Association, and American Academy of Developmental Medicine and Dentistry resources, among many others available through the AAN and CDC. Ensuring caregiver wellness likely has the added benefit of reducing the risk of stress-provoked abuse or neglect of your patients.

7. Ensure food and housing security.
It is critical to discuss basic needs in this population who is often financially compromised and under-employed. Discuss with your clinic or local hospital social worker regarding local food delivery/volunteer programs and shelters. Consider providing information about these resources to all of your patients at this time regardless of whether they endorse food or housing insecurity. For many patients and families, newfound financial hardships could be a source of embarrassment that they may be uncomfortable discussing.

8. Assert your focus on evidence-based practice.

Understandably heightened emotions and the desperate desire for treatments for COVID-19 has led to a surge of requests for immediate use of poorly-studied therapeutic regimens. Some of these treatments, if instituted empirically, can have serious consequences for individuals with IDD due to interactions with common medications they may already be taking. For example, chloroquine taken together with antidepressants like citalopram, fluoxetine, or antipsychotics like quetiapine can have potent QT prolonging effects. Urge your patients to not take these medications empirically and to consult with your or another physician familiar with their full medication list. Encourage them that a well-designed global trial is underway to determine effective treatments for COVID-19 quickly.

9. Care Coordination

Be clear which practitioner is supporting and caring for the individual’s needs for a specific issue and concern. Individuals with IDD often have complex healthcare and behavioral concerns. Many care providers maybe involved and responsible for particular social, medical and mental health issues.

10. Too much for one visit?

Consider prioritizing medication refills, crisis management, and food and housing security in your first tele-visit during the pandemic and subsequently following up in two weeks to re-assess. Ongoing, perhaps frequent, and short tele-neurology visits are useful for ensuring medical needs are met and have the added benefit of helping your patients combat social isolation.

Advocacy

As the global pandemic grows, healthcare leaders across the world engage in discussions about resource allocation strategies, though rife with ethical turmoil. Legal and ethical texts have eschewed the merits of a disability-based resource utilization approach, particularly where the disability in question is not, in and of itself, life limiting. Some have proposed a lottery system as the fairest method of resource allocation. Perhaps our job is not to offer such heart-wrenching and draconian alternatives but to instead assert that our patients’ lives have inherent value and that our patients have already demonstrated remarkable emotional and medical resiliency in a world that often counts them out.
It is our responsibility to advocate for personal protective equipment, not just for us as health care workers, but also sufficient for our vulnerable patients and their caregivers if they have to come in for maintenance medical care in the middle of this pandemic. It is our responsibility to advocate for a surge in the production of medical equipment such that life or death discussions about resource utilization become moot. To this end, we strongly encourage neurologists to become involved in collectively powerful endeavors to advocate for individuals with IDD (Table 3).

For the next pandemic

Echoing a call to arms following our last pandemic of H1N1 in 2009, it is critical to include those with IDD and their caregivers as a part of the team devoted to developing the next pandemic plan. We cannot appropriately care for individuals with IDD without being aware of their unique needs.

Ensure that crisis management plans are always clearly documented for your patients. Also ensure that your patients have copies of this crisis management plan and that they carry this plan with them when seeking urgent medical care.

If there can be any health-care silver lining to the COVID-19 pandemic, it is that this pandemic has prompted rapid adoption of tele-neurology services. Those who are medically vulnerable in a pandemic remain medically vulnerable outside of a pandemic. Tele-neurology follow-up visits may ultimately allow us to provide ongoing safe, equitable, patient-centered care long after this pandemic subsides.

Conclusions

The COVID-19 pandemic has created tremendous challenges for our society as a whole, including those with IDD and their support systems. It will be important to evaluate the health outcomes of individuals with IDD throughout the pandemic to determine if care practices in place were indeed sufficient.

The field of neurology, as it pertains to caring for adults with IDD, has extraordinary opportunities for growth; there are currently major deficits of education, training, and research targeting adult patients with IDD, despite more neurology patients living into adulthood. Without high quality provision of care, adults with IDD risk profound deterioration in their health and quality of life. Future work must include robust training programs that prepare neurologists to take care of patients with IDD as well as research to strengthen our ability to make evidence-based decisions treatment plans.

It is a moral and ethical imperative for all of us to pay attention to vulnerable populations, like those with IDD. Though the global pandemic has highlighted this, the imperative remains throughout every day of our practice. Our hope is that the above recommendations have practical implications regarding the care of those with IDD now, and also long after the pandemic is over.
Table 1. Suggestions for tele-neurology surveillance

<table>
<thead>
<tr>
<th>Symptoms to screen for in tele-neurology visit</th>
<th>Approach</th>
</tr>
</thead>
</table>
| Current ability to accomplish activities of daily living (ADLs) | • Define who supports patient with ADLs.  
  • Ensure backup plans in place if support personnel unable to care for patient.  
  • Confirm that infection-mitigation measures are in place for caregivers, including social distancing, handwashing, and PPE. |
| Current status of psychiatric co-morbidities | • When was the last episode of behavioral dysregulation that required administration of an abortive medication?  
  • Assess current management of mood and behavioral symptoms.  
  • Provide resources for virtual exercise, therapy, and social interactions to mitigate the effect that current social restrictions due to COVID-19 impact your patient’s mood. |
| Current status of sleep | • Assess current sleep hygiene and sleep schedule.  
  • Document use of medications to help with sleep. |
| Current status of tone | • Does the patient feel that their tone is currently well managed?  
  • Create a shared understanding of the most effective medications/injectables for the patient’s tone.  
  • Assess fit and use of orthotics, wheelchairs, and other assistive devices to maximize functioning and minimize discomfort. |
| Current status of pain | • If experiencing pain, document the location and settings in which pain is experienced.  
  • Discuss pain management current strategies, and devise plans for improvement if needed. |
| Current status of cognition | • In children, ensure that |


developmental progress is ongoing and that communication needs are being met.

- In adults, consider empiric standardized cognitive assessments, particularly in those who are at risk for progressive cognitive impairment like individuals with Down syndrome or epilepsy.

| Current status of medical comorbidities | • Emphasize importance of continued medical surveillance and preventative primary care. |

Table 2. Crisis Management Planning

<table>
<thead>
<tr>
<th>Discuss</th>
<th>Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms of COVID-19</td>
<td>Follow local protocols for testing and quarantine.</td>
</tr>
<tr>
<td>Depression and anxiety</td>
<td>Adjust medication, develop therapeutic strategies virtually, while maintaining physical distancing, before the symptoms worsen to require hospitalization.</td>
</tr>
<tr>
<td>Abuse and neglect</td>
<td>If at all possible, assess the patient alone via tele-neurology.</td>
</tr>
<tr>
<td>Seizure Frequency</td>
<td>Confirm adequate dosing and supply of seizure medications. Ensure documentation and shared understanding of seizure rescue plan.</td>
</tr>
<tr>
<td>Baclofen pump or equipment malfunctions</td>
<td>Discuss the symptoms of withdrawal and overdose. Have a plan in place for concerns for pump failure.</td>
</tr>
<tr>
<td>Muscle tone changes</td>
<td>Create a plan in the event of emerging dystonic crisis or status dystonicus.</td>
</tr>
<tr>
<td>Planning for potential inability to take oral medications</td>
<td>Create parenteral bridge plans for essential medications.</td>
</tr>
</tbody>
</table>
Table 3. Suggestions for advocacy supporting individuals with IDD

<table>
<thead>
<tr>
<th>Advocacy Option</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publicly available written or recorded commentary regarding equipment requirements to provide adequate medical care for the entire population</td>
<td>Letters written to your local newspaper, online blogs, or posted directly to social media can be made immediately available, are often easily shareable, and can educate your community about your needs as a medical provider and the needs of your patients.</td>
</tr>
<tr>
<td>Reporting of any signs of abuse or neglect</td>
<td>Though the risk of abuse and neglect is higher during the pandemic, reporting has decreased as people are become physically isolated by necessity. In addition to being vigilant for evidence of abuse or neglect, reporting these concerns to child protective services or law enforcement will be critical for keeping our patients safe.</td>
</tr>
<tr>
<td>Reaching out to your local news station offering to discuss your thoughts on the pandemic, pandemic response, and resource allocation</td>
<td>Neurologists are in a privileged position to educate the public. Given that we have particular expertise in the care requirements of individuals with IDD, we must advocate publicly for resources on their behalf.</td>
</tr>
<tr>
<td>Writing your senator and congressman regarding the abhorring nature of life valuation based on disability</td>
<td>Laws will be made in a vacuum free of neurologist voices, unless we make ours heard.</td>
</tr>
<tr>
<td>Voting whenever the opportunity is available</td>
<td>Elect allies of medical professionals and supporters of facilitating comprehensive care, particularly for medically complex patients like individuals with IDD.</td>
</tr>
<tr>
<td>Leading by example</td>
<td>For example, continuing ongoing comprehensive telecare health maintenance visits for individuals with IDD and publicizing these efforts to your colleagues may help them understand the special needs of individuals with IDD.</td>
</tr>
<tr>
<td>Advocate for visitation rights to help ensure the person with IDD has a caregiver with them during the hospital stay</td>
<td>A caregiver in the hospital will provide a comforting and supporting voice which will greatly reduce stress to the patient as well as improve outcomes of care.</td>
</tr>
</tbody>
</table>
Appendix 1: Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Solomon Sanders, MD</td>
<td>Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA</td>
<td>Drafted intellectual content and revised the manuscript for intellectual content; provided references.</td>
</tr>
<tr>
<td>Seth M. Keller, MD</td>
<td>Neurology Associates of South Jersey, Lumberton, NJ</td>
<td>Drafted and revised the manuscript for intellectual content.</td>
</tr>
<tr>
<td>Bhooma Aravamuthan, MD</td>
<td>Division of Pediatric Neurology, Department of Neurology, Washington University School of Medicine, St. Louis, MO</td>
<td>Drafted and revised the manuscript for intellectual content.</td>
</tr>
</tbody>
</table>

References


doi:10.1111/jsr.13052


18. Cerebral Palsy Now — Advancing Neurorecovery.

19. COVID-19 - NDSS.


33. Child abuse calls plunge during coronavirus as hospitals see more severe cases than usual - The Washington Post.
Caring for individuals with intellectual and developmental disabilities in the coronavirus disease 2019 crisis

Jessica Solomon Sanders, Seth Keller and Bhooma R. Aravamuthan

*Neurol Clin Pract* published online May 29, 2020
DOI 10.1212/CPJ.0000000000000886

This information is current as of May 29, 2020

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://cp.neurology.org/content/early/2020/09/10/CPJ.0000000000000886.full.html">http://cp.neurology.org/content/early/2020/09/10/CPJ.0000000000000886.full.html</a></th>
</tr>
</thead>
</table>
| Subspecialty Collections | This article, along with others on similar topics, appears in the following collection(s):  
COVID-19 [http://cp.neurology.org/cgi/collection/covid_19](http://cp.neurology.org/cgi/collection/covid_19)  
Equity, Diversity, and Inclusion (EDI) [http://cp.neurology.org/cgi/collection/all_equity_diversity_and_inclusion](http://cp.neurology.org/cgi/collection/all_equity_diversity_and_inclusion)  
Health disparities [http://cp.neurology.org/cgi/collection/health_disparities](http://cp.neurology.org/cgi/collection/health_disparities) |
| Errata | An erratum has been published regarding this article. Please see next page or: [http://cp.neurology.org/content/early/2020/09/10/CPJ.0000000000000967.full.pdf](http://cp.neurology.org/content/early/2020/09/10/CPJ.0000000000000967.full.pdf) |
| Permissions & Licensing | Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: [http://cp.neurology.org/misc/about.xhtml#permissions](http://cp.neurology.org/misc/about.xhtml#permissions) |
| Reprints | Information about ordering reprints can be found online: [http://cp.neurology.org/misc/addir.xhtml#reprintsus](http://cp.neurology.org/misc/addir.xhtml#reprintsus) |
Caring for individuals with intellectual and developmental disabilities in the COVID-19 crisis

An incorrect version of the article “Caring for individuals with intellectual and developmental disabilities in the COVID-19 crisis” by J. Solomon Sanders, S. Keller and B. Aravamuthan (Neurol Clin Pract May 2020; DOI: 10.1212/CPJ.0000000000000886) was originally published online ahead of print on May 29, 2020. A corrected version was posted on September 11, 2020. Please note that these errors do not affect the accuracy of the data or conclusions of the article. The editorial office regrets the error.

Reference